Evidence map›Paper›PMID 33632899›Full record

ArticleCancer research2021

Susceptibility-Associated Genetic Variation in

Dong Han, Jude N Owiredu, Bridget M Healy, Muqing Li, Maryam Labaf, Jocelyn S Steinfeld, Susan Patalano, Shuai Gao, Mingyu Liu, Jill A Macoska and 5 more

Open access · bronzeAbstract read
In one paragraph

Article in Cancer research, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed, 1 pooled it
1.2field-weighted citation impact, top 21% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 1 synthesis or guideline pooled it, 7 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Review
  4. Cancer research · 2021
    Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

15 authors at 4 institutions in 1 country.

Dong HanCenter for Personalized Cancer Therapy, University of Massachusetts Boston, Boston, Massachusetts.ORCID 0000-0002-6224-855X
Jude N OwireduCenter for Personalized Cancer Therapy, University of Massachusetts Boston, Boston, Massachusetts.
Bridget M HealyCenter for Personalized Cancer Therapy, University of Massachusetts Boston, Boston, Massachusetts.
Muqing LiCenter for Personalized Cancer Therapy, University of Massachusetts Boston, Boston, Massachusetts.
Maryam LabafDepartment of Mathematics, University of Massachusetts Boston, Boston, Massachusetts.ORCID 0000-0002-1215-0618
Jocelyn S SteinfeldDepartment of Biology, University of Massachusetts Boston, Boston, Massachusetts.ORCID 0000-0001-8809-7916
Susan PatalanoCenter for Personalized Cancer Therapy, University of Massachusetts Boston, Boston, Massachusetts.
Shuai GaoCenter for Personalized Cancer Therapy, University of Massachusetts Boston, Boston, Massachusetts.
Mingyu LiuCenter for Personalized Cancer Therapy, University of Massachusetts Boston, Boston, Massachusetts.
Jill A MacoskaCenter for Personalized Cancer Therapy, University of Massachusetts Boston, Boston, Massachusetts.ORCID 0000-0001-8471-2221
Kourosh ZarringhalamDepartment of Mathematics, University of Massachusetts Boston, Boston, Massachusetts.
Kellee R SiegfriedDepartment of Biology, University of Massachusetts Boston, Boston, Massachusetts.ORCID 0000-0002-7951-392X
Xin YuanHematology-Oncology Division, Department of Medicine, Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, Massachusetts.
Timothy R RebbeckDivision of Population Sciences, Dana-Farber Cancer Institute and Harvard TH Chan School of Public Health, Boston, Massachusetts.
Changmeng CaiCenter for Personalized Cancer Therapy, University of Massachusetts Boston, Boston, Massachusetts. changmeng.cai@umb.edu.
Boston University · USUniversity of Massachusetts Boston · USBeth Israel Deaconess Medical Center · USDana-Farber Cancer Institute · US

Funding

UMass Boston-DF/HCC U54 Partnership (2 of 2)U54CA156734 · NCI · UNIVERSITY OF MASSACHUSETTS BOSTON · PI Jan Mutchler · 2010 to 2026
$24.9M
Role of Beta-Catenin in Urinary DysfunctionU54DK104310 · NIDDK · UNIVERSITY OF WISCONSIN-MADISON · PI RICKE, WILLIAM A · 2014 to 2023
$12.8M
Initiative for Maximizing Student Diversity at UMass BostonR25GM076321 · NIGMS · UNIVERSITY OF MASSACHUSETTS BOSTON · PI COLON-CARMONA, ADAN, SKVIRSKY, RACHEL · 2008 to 2022
$4.5M
Precision Interception of Aggressive Prostate Cancer in African American MenP20CA233255 · NCI · DANA-FARBER CANCER INST · PI REBBECK, TIMOTHY R · 2018 to 2020
$3.2M
Study the Mechanism of Retinoblastoma Protein Mediated Androgen Receptor Transcriptional Repression Activity on DNA ReplicationR01CA211350 · NCI · UNIVERSITY OF MASSACHUSETTS BOSTON · PI CAI, CHANGMENG · 2017 to 2021
$1.7M
NCI NIH HHS P20 CA233255NCI NIH HHS R01 CA211350NCI NIH HHS U54 CA156734NIDDK NIH HHS U54 DK104310NIGMS NIH HHS R25 GM076321
6 · The paper itself

Abstract

Although American men of European ancestry represent the largest population of patients with prostate cancer, men of African ancestry are disproportionately affected by prostate cancer, with higher prevalence and worse outcomes. These racial disparities in prostate cancer are due to multiple factors, but variations in genomic susceptibility such as SNP may play an important role in determining cancer aggressiveness and treatment outcome. Using public databases, we have identified a prostate cancer susceptibility SNP at an intronic enhancer of the neural precursor expressed, developmentally downregulated 9 (

Indexed as

Adaptor Proteins, Signal TransducingAnimalsDisease ProgressionGenetic Predisposition to DiseaseGenetic VariationHumansMaleMiceMice, SCIDProstatic NeoplasmsTransfectionZebrafishAdaptor Proteins, Signal TransducingNEDD9 protein, human

Identifiers

PMID33632899
PMCPMC8286295
OpenAlexW3130239433

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.